Latham & Watkins Advises CytomX Therapeutics on US$100 Million Underwritten Offering of Common Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, has announced the pricing of an underwritten offering of 76,923,076 shares of its common stock at an offering price of US$1.30 per share, before underwriting discounts and commissions. All of the shares are being offered by the company. The gross proceeds from the offering are expected to be approximately US$100 million before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on May 13, 2025, subject to customary closing conditions.

Latham & Watkins represents CytomX Therapeutics in the offering with a corporate team led by Bay Area partners Mark Roeder and John Williams, with associates Greg Van Buiten, Lexi Zintel, and Bridget Carmody. Advice was also provided on intellectual property matters by San Diego/Bay Area partner Chris Hazuka, with associate Patrick Chew; on tax matters by Bay Area partner Grace Lee, with associate Dennis Poehland; on regulatory matters by Bay Area partner Betty Pang and Washington, D.C. counsel Chad Jennings, with associate Evan Miller; on data privacy matters by Bay Area partner Heather Deixler; and on compensation and benefits matters by Bay Area partner James Metz.